8-K: Allurion Faces NYSE Delisting, Plans Appeal

Allurion Technologies received a NYSE delisting notice due to non-compliance with listing standards but plans to appeal, expecting continued trading during the process.

Summary

• Allurion Technologies, Inc. received a delisting notice from the New York Stock Exchange (NYSE) on March 2, 2026.
• The notice indicates non-compliance with NYSE Section 802.01B, which requires listed companies to maintain at least $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis.
• The Company previously received a non-compliance notice on August 29, 2024.
• Allurion intends to appeal the delisting determination to a Committee of the Board of Directors of the Exchange.
• The Company's securities are expected to continue trading on the NYSE during the appeal process, subject to compliance with other listing requirements.
• Efforts to regain compliance include discussions with creditors and security holders, as well as capital raising initiatives.
• Allurion has an agreement with its largest creditor to exchange outstanding debt for preferred stock at a substantial premium to the current trading price.
• A warrant inducement transaction was completed on February 24, 2026.
• Recent FDA approval on February 20, 2026, for the Allurion Gastric Balloon System is viewed by management as a catalyst for regaining compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the delisting notice, reflecting fundamental non-compliance with financial listing standards. While the appeal and recent FDA approval offer some mitigation, the uncertainty and potential consequences of delisting are severe.

Positives

• Allurion intends to appeal the delisting notice, allowing its common stock and warrants to continue trading on the NYSE during the appeal process.
• The Company recently received FDA approval for its Allurion Gastric Balloon System on February 20, 2026, which management believes will catalyze efforts to regain compliance.
• Allurion has an agreement with its largest creditor to exchange outstanding debt for preferred stock at an exchange ratio representing a substantial premium to the current trading price.
• A warrant inducement transaction was completed on February 24, 2026, as part of ongoing efforts to regain compliance.

Negatives

• Allurion received a delisting notice from the NYSE for failing to meet continued listing standards, specifically maintaining at least $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis.
• There is no assurance that the appeal will be successful or that the Company will regain compliance with NYSE standards or be able to list on another nationally recognized exchange.
• Potential delisting could negatively impact the liquidity and market price of the Company's Common Stock and Warrants.
• Delisting could reduce the number of investors willing to hold or acquire the Company's securities, potentially hindering future equity financing.
• Delisting could limit the Company's ability to use a registration statement for freely tradable securities, restricting access to public capital markets.
• The Company's ability to provide equity incentives to employees could be impaired if delisted.

Risks

• The ability of the Company to maintain regulatory approvals for and successfully commercialize its products and offerings, including the Allurion Balloon.
• The timing of, and results from, the Company's clinical studies and trials.
• The evolution of the markets in which the Company competes.
• The ability of the Company to defend its intellectual property and satisfy regulatory requirements.
• The impact of global economic conditions and geopolitical events on the Company's business.
• The risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates.
• The risk that the Delisting Notice and noncompliance with NYSE continued listing standards may impact the Company's results of operations, business operations, reputation, and the trading prices and volatility of its common stock.
• The Company's ability to regain compliance with NYSE continued listing standards or to satisfy the initial listing standards of another nationally recognized securities exchange.
• The Company's ability to complete a transaction or transactions to achieve compliance with the Exchange's requirements on acceptable terms, or at all.

Future Outlook

Allurion intends to appeal the NYSE delisting determination and expects its common stock to continue trading on the NYSE during the appeal process. The Company is actively working to regain compliance with NYSE listing standards or to qualify for listing on another nationally recognized securities exchange, leveraging recent FDA approval as a catalyst. However, there is no guarantee of success in these efforts.

Management Comments

• "We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American."
• "The first step in our plan was receiving FDA approval on February 20, 2026."
• "We believe this approval will catalyze the remaining parts of our plan to regain compliance or relist, and we expect our common stock to remain trading on the NYSE while we execute this plan."

Industry Context

StockSavvy.ai notes that Allurion operates in the competitive weight loss industry, which is currently experiencing significant shifts due to the rise of GLP-1 therapies. The Company's recent FDA approval for its Gastric Balloon System positions it to potentially offer an alternative or complementary solution in this evolving market, but the immediate challenge of maintaining its stock exchange listing overshadows these product-related developments.

Stakeholder Impact

• Shareholders: Potential negative impact on liquidity and market price of Common Stock and Warrants, reduced investor interest, and limited access to public capital markets.
• Employees: Impaired ability to provide equity incentives.

Next Steps

• Allurion intends to appeal the NYSE's determination to commence delisting proceedings and will request a review by a Committee of the Board of Directors of the Exchange.
• The Company will continue its efforts to regain compliance with NYSE continued listing requirements or gain compliance with initial listing requirements of another nationally recognized securities exchange.
• Ongoing discussions and negotiations with existing creditors and security holders.
• Continued capital raising efforts.

Key Dates

Recommendation

The delisting notice from the NYSE due to failure to meet financial listing standards represents a severe risk to Allurion's stock. While the company is appealing and has recent FDA approval, the fundamental non-compliance and the high uncertainty of a successful appeal or alternative listing make the stock highly speculative and vulnerable to significant downside. A seasoned investor would likely consider selling to mitigate exposure to potential delisting and associated liquidity and valuation issues.

Keywords

Allurion Technologies, NYSE delisting, listing standards, stockholders equity, market capitalization, FDA approval, weight loss, gastric balloon, capital raise, corporate governance, ALUR